Work

Radioembolization Versus Bland or Chemoembolization for Liver-Dominant Neuroendocrine Tumors: Is It an Either/Or Question?

Year: 2021

Type: article

Abstract: Hepatic arterial embolization has been used for decades to treat liver-dominant metastatic neuroendocrine tumors (NETs). During the 1970s–1990s, transarterial bland hepatic arterial embolization (TAE) and chemoembolization (TACE) techniques were developed ([ 1 ][1],[ 2 ][2]). Numerous studies have

Source: Journal of Nuclear Medicine

DOI: 10.2967/jnumed.121.263041

Authors: Strosberg Jonathan, Ghassan El-Haddad, Taymeyah Al-Toubah, Diane Reidy-Lagunes, Etay Ziv, Armeen Mahvash, Arvind Dasari, Philip A. Philip, Michael C. Soulen

Institutions: Moffitt Cancer Center, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, The Barbara Ann Karmanos Cancer Institute, University of Pennsylvania

Language: English

Topic: Neuroendocrine Tumor Research Advances

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Boston Scientific Corporation, Novocure, BeiGene, Incyte, Advanced Accelerator Applications, NGM Biopharmaceuticals, Natera, Eisai, Ipsen, Sirtex Medical, Genentech, Daiichi Sankyo Europe

OpenAlex ID: W3199660281

FWCI: 1.222

Cites: 25

Cited by: 15

Related to: 10